News

In a placebo-controlled, double-blind, four-week Phase IIa study, INT131 administration demonstrated a significant improvement in fasting plasma glucose compared to baseline and placebo at doses of 1mg and

The six-month Phase III study will involve up to 750 patients with Type-1 diabetes mellitus in 36 centers located in the US, Canada, Russia and eastern Europe. The

Under the terms of the collaboration, Laboratory Corporation of America Holdings (LabCorp) will be Vanda’s exclusive commercialization partner for tests for genetic markers of the Fanapta program. Vanda

This research will test the efficacy of an ImmunoVaccine Technologies’s (IVT) pandemic influenza vaccine formulation delivered using Bioject’s flagship Bioject B2000 device. The research will compare the onset,

Under the terms of the agreement Jiangsu Aosaikang Pharmaceutical (ASK) will pay Access an upfront fee and subsequent milestone payments along with a double digit royalty upon commercialization

Lev has also announced plans to launch LevCare, a program designed to ensure that patients have ready access to Cinryze once it becomes commercially available in the US.

The ongoing Phase II single-arm study of GCS-100 given intravenously as a single agent to relapsed chronic lymphocytic leukemia (CLL) patients is designed to evaluate the effects of

SpePharm’s Loramyc 50mg, a muco-adhesive buccal tablet of miconazole, is indicated for the treatment of oropharyngeal candidiasis (OPC) in immunocompromised patients. At the same time, Loramyc has been

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include